These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms. Jiménez M; Fernández-Naval C; Navarro V; Novoa S; Martinez-Gallo M; Medina D; Andrés C; Antón A; Peralta S; Pujadas G; Hernández C; Pagès C; Roldán E; Pumarola T; Gironella M; Ruiz-Camps I; Martínez-Gómez X; Valcárcel D; Hernández M; Bosch F; Crespo M; Esperalba J; Abrisqueta P Am J Hematol; 2023 Aug; 98(8):1204-1213. PubMed ID: 37151135 [TBL] [Abstract][Full Text] [Related]
6. The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies. Xu J; Lan X; Zhang L; Zhang X; Zhang J; Song M; Liu J Front Public Health; 2023; 11():1165611. PubMed ID: 37325336 [TBL] [Abstract][Full Text] [Related]
7. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies. Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148 [TBL] [Abstract][Full Text] [Related]
8. Vaccination for SARS-CoV-2 in Hematological Patients. Riccardi N; Falcone M; Yahav D Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855 [TBL] [Abstract][Full Text] [Related]
10. Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients. Schietzel S; Anderegg M; Limacher A; Born A; Horn MP; Maurer B; Hirzel C; Sidler D; Moor MB RMD Open; 2022 Feb; 8(1):. PubMed ID: 35115385 [TBL] [Abstract][Full Text] [Related]
11. Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments. Pfannes R; Pierzchalski A; Maddalon A; Simion A; Zouboulis CC; Behre G; Zenclussen AC; Westphal S; Fest S; Herberth G Front Immunol; 2023; 14():1087996. PubMed ID: 37187728 [TBL] [Abstract][Full Text] [Related]
12. Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis. Wankhede D; Grover S; Hofman P Vaccine; 2023 Mar; 41(11):1791-1798. PubMed ID: 36792435 [TBL] [Abstract][Full Text] [Related]